Related Experiment Video
Updated: Mar 20, 2026

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus
Published on: June 23, 2022
[Treatment adherence with levetiracetam: a non-interventionist retrospective observation-based study]
P J Serrano-Castro1, J A Mauri-Llerda2, A Garcia3
1Hospital Torrecardenas, 04009 Almeria, Espana.
Introduction:
Treatment adherence is a factor that is affecting the effectiveness of antiepileptic drugs. Levetiracetam is a drug whose effectiveness and safety is well established and is available in different oral formulations (granulates in sachets, tablets, oral solution), but information on treatment adherence/compliance with these oral formulations is limited.
Aim:
To determine treatment adherence with levetiracetam formulations (granulates in sachets, tablets) in adult and elderly people.
Patients And Methods:
Retrospective observational non-interventionist study. During the three months before the study patients should be treated with levetiracetam (granulates in sachets or tablets), either alone or in combination. Compliance tests (Green-Morisky modified test) as well as a satisfaction questionnaire investigator and patient/caregiver is assessed. Data were analyzed using SPSS v. 21.0 program.
Results:
A total of 466 patients completed the study. The average age was 52.75 ± 19.17 years old and the average over 65 years of 72.79 ± 6.15. 55.4% were men. Compliance is related to the variable 'pharmaceutical formulation' and with age (p = 0.031). The risk of non-compliance was 86.4% higher among those taking tablets versus granulates in sachets of levetiracetam (odds ratio: 1.864). Likewise, the non-compliance was greater among patients over 65 years. The non-compliance was related to attributing of memory failures.
Conclusions:
Patients older are more difficult to compliance. The granulates levetiracetam in sachets improves compliance.
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Therapeutic Drug Monitoring: Affecting Factors
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Bioavailability Study Design: Healthy Subjects Versus Patients
Drug Therapy
Antianxiety Medications

